A systematic review on the efficacy and safety of disease-modifying drugs in relapsing-remitting multiple sclerosis, including 50 studies with 36,541 participants and 29 drugs, was recently published by our review group in the Cochrane Library.

Through a network meta-analysis, both direct and indirect comparisons were considered.

The review was used as the evidence base for the inclusion of the first 3 drugs for multiple sclerosis in the 2023 WHO Essential Medicines List.

A Cochrane review has helped inform an important decision with global public health implications. People with relapsing-remitting multiple sclerosis in countries with limited resources will have greater access to effective treatments.

The review is available in full text at this link